GlassScriptPhysician profile
Tricia Brenner
NPI 1215085907
$9,848.07
in general payments reported to CMS, 2019-2025
26 companies · $1,359 in 2025
The $1,359 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,759 · 2020: $196 · 2021: $582 · 2022: $829 · 2023: $3,939 · 2024: $1,184 · 2025: $1,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,178 · Travel and Lodging: $2,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,178.19 |
| Travel and Lodging | $2,302.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $3,777.57 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $1,141.76 | 2019-2025 | Precision 1, Total30, Precision7 |
| Johnson & Johnson Vision Care, INC. | $945.56 | 2019-2025 | Acuvue |
| Abbvie INC. | $482.69 | 2022-2025 | Lumigan, Durysta, Alphagan P |
| Bausch & Lomb Americas INC. | $452.45 | 2022-2025 | Miebo, Xiidra, Infuse |
| Astellas Pharma US INC | $367.02 | 2023-2025 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $304.50 | 2019-2021 | |
| Allergan, INC. | $304.24 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $282.81 | 2021-2025 | |
| Hoffmann-La Roche Limited | $274.47 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $232.39 | 2019-2022 | |
| Abb Con-Cise Optical Group LLC | $205.76 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $174.46 | 2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $146.56 | 2021 | |
| Harrow Eye, LLC | $142.69 | 2025 | Vevye |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $115.61 | 2024 | Syfovre |
| Genzyme Corporation | $113.85 | 2019 | |
| Oyster Point Pharma, INC. | $111.36 | 2024 | Tyrvaya |
| Optos, INC. | $86.26 | 2019 | |
| Optovue, INC. | $66.66 | 2019 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Sight Sciences, INC. | $19.99 | 2020 | |
| Eyevance Pharmaceuticals LLC | $17.95 | 2021 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Dompe US, INC. | $13.38 | 2022 | |
| Thea Pharma INC. | $12.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tricia Brenner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.